DJIA 17,550.69 -47.51 -0.27%
NASDAQ 5,105.55 -9.84 -0.19%
S&P 500 2,093.32 -4.72 -0.22%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

32.75 -0.75 (-2.24%)

REAL-TIME: Last trade at

Extended Hours: $32.75 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

SRPT $32.75 -2.24%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $33.50
Previous Close $33.50
Daily Range $32.43 - $33.83
52-Week Range $11.33 - $34.66
Market Cap $1.4B
P/E Ratio -9.44
Dividend (Yield) $0.00 (0.0%)
Volume 803,408
Average Daily Volume 1,165,070
Current FY EPS -$4.92

Sector

Healthcare

Industry

Drug Makers

Sarepta Therapeutics (SRPT) Description

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology. Website: http://www.sarepta.com/

News & Commentary

3 Soaring Clinical-Stage Biotechs, and 1 to Buy

One Motley Fool digs into three top performing biotech stocks and discovers one that may still be worth buying.

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplusĀ® platform

FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs

Short-Sellers Betting Against These Biotechs

What Propelled Sarepta Therapeutics' Stock 19% Higher in June?

Clinical-stage biopharmaceutical company Sarepta Therapeutics roared higher in June. Find out what was behind this big move and whether it has the legs to push higher.

Catabasis Up on Fast Track Status for DMD Drug CAT-1004 - Analyst Blog

Several Biotech Stocks Indicating A Macro Short Strategy

The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Pre

The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases

Cramer Is Flying Southwest, Won't Recommend Sarepta Therapeutics

See More SRPT News...

SRPT's Top Competitors

SRPT $32.75 (-2.24%)
Current stock: SRPT
AMGN $174.80 (-0.45%)
Current stock: AMGN
GILD $118.87 (-0.61%)
Current stock: GILD
CELG $131.08 (-0.30%)
Current stock: CELG